S&P/ASX 200 Index (ASX: XJO) shares are down 0.4% to 8,772.2 points on Thursday.
Among the 11 market sectors, healthcare is in the lead today, up 2.7%, amid signs of a meaningful sector rebound.
The energy sector is the drag on Thursday, down 2.5%, as the supply outlook improves in the Middle East.
Trading Economics analysts reported that growing confidence in a lasting peace deal had prompted more tankers to transit the Strait of Hormuz with their tracking signals on.
Supply has also increased across key segments of the market, with buyers facing a surge of crude offers from the Middle East and other exporting regions, including West Africa.
In addition, a temporary US waiver permitting purchases of already-loaded Iranian oil is expected to further boost available supply.
Meanwhile, three experts let us in on their opinions of three ASX shares.
Let's check them out.
Image source: Getty Images
Capricorn Metals Ltd (ASX: CMM)
The Capricorn Metals share price is $11.98, down 5.5% today and down 17% in the calendar year to date (YTD).
David Coates from Bell Potter has a buy rating on this ASX gold share.
Coates said:
CMM is a sector leading gold producer, unhedged and debt free. It is fully funded to grow production from ~120kozpa to ~300kozpa from two gold mines in WA, each with +10 year mine lives.
CMM is run by a management team that has an excellent track record of delivery.
Our NPV-based valuation is up marginally to $16.25/sh.
Chrysos Corporation Ltd (ASX: C79)
The Chrysos Corporation share price is $5.65, down 3.4% today and down 23% YTD.
Toby Grimm from Baker Young has a hold recommendation on this ASX industrials share.
On The Bull this week, Grimm said:
The company combines science and software to create technology solutions for the global mining industry. The company's flagship product is PhotonAssay.
A pull back in gold prices, if protracted, presents a potential headwind. However, we're encouraged by expansion into South America, where we see a large copper analysis opportunity as C79 continues to branch out from gold.
The company's decision to upsize its debt facility to $200 million reflects management's confidence in the near term growth runway.
In our view, the stock offers significant recovery potential given it was recently trading at a substantial discount to its February highs.
Cochlear Ltd (ASX: COH)
The Cochlear share price is $115.31, up 1.6% today and down 56% YTD.
Niv Dagan from Peak Asset Management has a sell rating on this ASX healthcare share.
He explained:
Hospital capacity constraints amid softer consumer sentiment and reduced referral activity are weighing on implant volumes, while cost base restructuring is likely to impact earnings in the near term.
In April, the hearing implants maker materially reduced its fiscal year 2026 underlying net profit guidance to between $290 million and $330 million from between $435 million from $460 million in February.
The downgrade was a response to weaker than expected demand in developed markets amid Middle East uncertainty, lower margins and foreign exchange headwinds.
